2. End Stage Renal Disease: Chapter 1: Incidence, Prevalence, Patient Characteristics, and Treatment Modalities. (USRDS) United States Renal Data System, Annual Data Report (2020). Available at: www.usrds.org.
3. Kuhlmann MK. Management of CKD-MBD. In: Misra M editor. Dialysis in the older adult. New York: Springer Science Business Media; 2016. p.109-21.10.1007/978-1-4939-3320-4_10
4. Pelletier S, Roth H, Bouchet JL, Drueke T, London G, Fouque D, et al. Mineral and bone disease pattern in elderly haemodialysis patients. Nephrol Dial Transplant. 2010;25(9):3062-70.10.1093/ndt/gfq12820237058
5. Kiss I, Kiss Z, Ambrus C, Szabo A, Szegedi J, Balla J et al. Age-dependent parathormone levels and different CKD-MBD treatment practices of dialysis patients in Hungary - results from a nationwide clinical audit. BMC Nephrol. 2013;14:155.10.1186/1471-2369-14-155372025523865464
6. Wang J, Bieber ВА, Hou F-F, Port FK, Anand S. Mineral and bone disorder and management in the China Dialysis Outcomes and Practice Patterns Study. Chin Med J (Engl). 2019;132(23):2775-82.10.1097/CM9.0000000000000533694006831856047
7. Yankova M, Todorov V, Ruseva A, Todorova G, Gencheva I. [Vitamin D status and risk factors for 25(ОН)D deficiency in patients with chronic kidney disease]. Nephrol Dial Transplant. 2021;27(2):26-31. Bulgarian
8. Kidney Disease: Improving Global Outcomes, (KDIGO) clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009;76 Suppl 113:S1-S130.